[Skip to Content]
[Skip to Content Landing]
Views 253
Citations 0
Editorial
June 13, 2018

The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication

Author Affiliations
  • 1Department of Neurosciences, Katholieke Universiteit Leuven, Kortenberg, Belgium
  • 2University Psychiatric Centre, Katholieke Universiteit Leuven, Kortenberg, Belgium
JAMA Psychiatry. Published online June 13, 2018. doi:10.1001/jamapsychiatry.2018.1080

Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe.1-3 As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.

First Page Preview View Large
First page PDF preview
First page PDF preview
×